Spots Global Cancer Trial Database for imatinib
Every month we try and update this database with for imatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | NCT01275196 | Chronic Myeloid... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer | NCT03170180 | Stomach Neoplas... | Sunitinib Gefitinib Imatinib | 20 Years - | Samsung Medical Center | |
| Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL | NCT05071482 | Acute Leukemia | Flumatinib Imatinib | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy | NCT02685046 | Colonic Neoplas... | Imatinib | 18 Years - | UMC Utrecht | |
| Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) | NCT02260505 | Gastrointestina... Resected Gastro... Non-metastatic High Risk of Re... KIT Gene Mutati... | Imatinib mainte... | 18 Years - | Centre Leon Berard | |
| Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting | NCT00877045 | Gastrointestina... | 18 Years - | SCRI Development Innovations, LLC | ||
| Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy | NCT02685046 | Colonic Neoplas... | Imatinib | 18 Years - | UMC Utrecht | |
| Frontline Asciminib Combination in Chronic Phase CML | NCT03906292 | Chronic Myeloid... | Imatinib Nilotinib 300 m... Dasatinib Asciminib | 18 Years - | University of Jena | |
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | NCT00852566 | Chronic Myeloid... | Imatinib Dasatinib | 18 Years - | Norwegian University of Science and Technology | |
| Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib | NCT01564836 | Chronic Myeloid... Imatinib Complete Molecu... | Imatinib treatm... | 18 Years - | Seoul St. Mary's Hospital | |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma | NCT04598009 | Melanoma Stage ... Melanoma Stage ... | Binimetinib Imatinib | 18 Years - | University of California, San Francisco | |
| A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | NCT00481247 | Myeloid Leukemi... | Dasatinib Imatinib | 18 Years - | Bristol-Myers Squibb | |
| Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST) | NCT00812240 | Gastrointestina... | Masitinib Imatinib | 18 Years - | AB Science | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | NCT01077544 | Chronic Myeloid... Acute Lymphobla... | Nilotinib | 1 Year - 17 Years | Novartis | |
| Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | NCT06219733 | Dermoid | Vactosertib Imatinib | 18 Years - | MedPacto, Inc. | |
| Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) | NCT00237120 | Chronic Myeloge... | Imatinib | 15 Years - 74 Years | Novartis | |
| A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | NCT05152472 | Unresectable Ga... Locally Advance... Metastatic Gast... | Atezolizumab 12... Imatinib 400 MG | 18 Years - | Centre Leon Berard | |
| Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST | NCT00500188 | Gastrointestina... | Imatinib Mesyla... | - | M.D. Anderson Cancer Center | |
| Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST | NCT02413736 | Sarcoma | Imatinib | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib | NCT01593254 | Chronic Phase C... | Imatinib Dasatinib | 18 Years - | Bristol-Myers Squibb | |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | NCT02881086 | Acute Lymphobla... Lymphoblastic L... | Rituximab Nelarabine PEG-Asparaginas... Cranial irradia... Imatinib Idarubicin Dexamethasone Cyclophosphamid... Fludarabine Vincristine Mercaptopurine VP16 Daunorubicin (D... Methotrexate Stem cell trans... Cytarabine Vindesine Adriamycin Prednisolone | 18 Years - 55 Years | Goethe University | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | NCT00402662 | Metastatic Mela... | everolimus Imatinib | 18 Years - | Yale University | |
| Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL | NCT02462538 | ALK+ Anaplastic... | Brentuximab ved... Imatinib | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer | NCT00485485 | Head and Neck C... Squamous Cell C... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00982488 | Leukemia | Dasatinib Imatinib | 18 Years - | Bristol-Myers Squibb | |
| STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia | NCT00376467 | Acute Lymphobla... | Imatinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) | NCT00237172 | Gastrointestina... | Imatinib Mesyla... | 20 Years - 74 Years | Novartis | |
| Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib | NCT00461929 | Chronic Myeloid... Gastrointestina... Chromosome Abno... | bone marrow asp... | 18 Years - | University Health Network, Toronto | |
| Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey | NCT01188278 | Leukemia, Myelo... | Imatinib | 18 Years - | Bristol-Myers Squibb | |
| Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia | NCT00333840 | Chronic Myeloge... | imatinib mesila... interferon-alph... cytarabine (ARA... | 18 Years - 70 Years | Novartis | |
| Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma | NCT04042597 | Effect of Drugs Quality of Life Chordoma Advanced Cancer | Anlotinib Hydro... | 18 Years - | Peking University People's Hospital | |
| Imatinib TDM in GIST | NCT05493215 | Gastrointestina... | Imatinib | 18 Years - | University of Kentucky | |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | NCT01506336 | Gastro Intestin... | masitinib sunitinib | 18 Years - | AB Science | |
| Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | NCT02894645 | Acute Lymphobla... | Prednisolone Dexamethasone L-Asparaginase Vincristine Methotrexate Daunorubicin Doxorubicin Cyclophosphamid... Cytarabine 6-Mercaptopurin... Thioguanine Fludarabine Imatinib | 1 Year - 17 Years | National University Hospital, Singapore | |
| A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies | NCT02352558 | Hematologic Mal... | BBI608 Dexamethasone Bortezomib Imatinib Ibrutinib | 18 Years - | Sumitomo Pharma America, Inc. | |
| Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease | NCT03844360 | Hematological N... | Bortezomib Eltrombopag Imatinib dasatinib Pegaspargase Anti-Infective ... PEGylated Recom... | 1 Day - 18 Years | Shandong University | |
| Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy | NCT02461849 | Advanced, Refra... | Imatinib | 20 Years - | Samsung Medical Center | |
| First-line Therapy of Stage IV Colorectal Cancer | NCT00784446 | Stage IV Colore... | Oxaliplatin, Ca... | 18 Years - | University of Cologne | |
| Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors | NCT00580281 | Gastric Cancer Leukemia Chronic Myeloge... | blood test, uri... | - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase | NCT04070443 | Philadelphia Ch... BCR-ABL Positiv... | Ponatinib Imatinib | 18 Years - 65 Years | Centre Leon Berard | |
| Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib | NCT00461929 | Chronic Myeloid... Gastrointestina... Chromosome Abno... | bone marrow asp... | 18 Years - | University Health Network, Toronto | |
| Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | NCT00130195 | Acute Lymphobla... | imatinib cyclophosphamid... daunorubicin vincristine prednisolone methotrexate cytarabine dexamethasone | 15 Years - 64 Years | Japan Adult Leukemia Study Group | |
| Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) | NCT00116935 | Sarcoma | imatinib mesyla... imatinib imatinib | 18 Years - | Scandinavian Sarcoma Group | |
| Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors | NCT00390156 | Unspecified Adu... | bevacizumab cyclophosphamid... imatinib | 18 Years - | University of California, San Francisco | |
| Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia | NCT01460693 | Myeloid Leukemi... | Imatinib Dasatinib | 18 Years - | Newcastle University | |
| Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer | NCT00372476 | Breast Cancer | Imatinib and Vi... | 18 Years - | Novartis | |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | NCT00493181 | Leukemia Chronic Myeloge... Chronic Myeloid... | Interleukin-11 ... | - | M.D. Anderson Cancer Center | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib | NCT05734105 | GIST | Ripretinib Sunitinib | 18 Years - | Deciphera Pharmaceuticals LLC | |
| Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib | NCT01506336 | Gastro Intestin... | masitinib sunitinib | 18 Years - | AB Science | |
| A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) | NCT04578847 | Chronic Myeloid... Chronic Myeloid... BCR-ABL Positiv... | Imatinib Nilotinib Dasatinib Bosutinib | 18 Years - | National Research Center for Hematology, Russia | |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | NCT02881086 | Acute Lymphobla... Lymphoblastic L... | Rituximab Nelarabine PEG-Asparaginas... Cranial irradia... Imatinib Idarubicin Dexamethasone Cyclophosphamid... Fludarabine Vincristine Mercaptopurine VP16 Daunorubicin (D... Methotrexate Stem cell trans... Cytarabine Vindesine Adriamycin Prednisolone | 18 Years - 55 Years | Goethe University | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) | NCT00199186 | Philadelphia Po... Lymphoid Blasti... | imatinib vincristine cyclophosphamid... cytosine arabin... dexamethasone idarubicin methotrexate (i... AraC (intrathec... dexamethasone (... | 56 Years - | Johann Wolfgang Goethe University Hospital | |
| A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia | NCT03589326 | Philadelphia Ch... | Ponatinib Imatinib Vincristine Dexamethasone Cytarabine Methotrexate Prednisone | 18 Years - | Takeda | |
| Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma | NCT00115739 | Thyroid Cancer | Imatinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database | NCT05286528 | Chronic Myeloid... | Bosutinib Imatinib Nilotinib Dasatinib Ponatinib | - | Pfizer | |
| Safety Assessment of a Multipeptide-gene Vaccine in CML | NCT00455221 | Leukemia, Myelo... | Bcr-abl multipe... Cytokine gene a... | 18 Years - 65 Years | Tehran University of Medical Sciences | |
| Role of Gene Variation in Effectiveness of Gleevec Treatment | NCT00342056 | Cancer Breast Cancer | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| ALL Adult Consortium Trial: Adult ALL Trial | NCT00476190 | Acute Lymphobla... | Doxorubicin Cytarabine Methotrexate Vincristine Cyclophosphamid... Methylprednison... Hydrocortisone ... Dexamethasone 6-MP PEG-Asparaginas... Imatinib Etoposide Radiation Thera... E. coli Asparag... | 18 Years - 50 Years | Dana-Farber Cancer Institute | |
| Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance | NCT01819389 | Leukemia, Myelo... | Imatinib and Ni... | 18 Years - | Hospital Universitario Dr. Jose E. Gonzalez | |
| TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | NCT00415909 | Chronic Myeloge... | Imatinib Mesyla... TALL-104 cells | 18 Years - | M.D. Anderson Cancer Center | |
| Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | NCT00103844 | Chronic Myeloid... Philadelphia-Po... | Dasatinib Imatinib | 18 Years - | Bristol-Myers Squibb | |
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients | NCT01275196 | Chronic Myeloid... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients | NCT03515018 | Leukemia, Chron... | hydroxyurea Imatinib | 16 Years - | First Affiliated Hospital of Harbin Medical University | |
| STI571 ProspectIve RandomIzed Trial: SPIRIT | NCT00219739 | Chronic Myeloid... | Imatinib mesyla... Imatinib mesyla... Imatinib 400 mg... Imatinib mesyla... | 18 Years - | Poitiers University Hospital | |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | NCT04677439 | Flumatinib Chronic Myeloid... Imatinib | Flumatinib | 18 Years - | Shenzhen Second People's Hospital | |
| Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia | NCT00040105 | Leukemia, Myelo... | Zarnestra (R115... Gleevec (Imatin... | 16 Years - | M.D. Anderson Cancer Center | |
| Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy. | NCT00149136 | Acute Lymphocyt... | imatinib | 55 Years - 90 Years | Hospices Civils de Lyon | |
| Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | NCT00760877 | CHRONIC MYELOGE... | Nilotinib Imatinib | 18 Years - | Novartis | |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation | NCT01243489 | Chronic Myeloge... | compliance supp... | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer | NCT01048320 | Advanced Pancre... | Gemcitabine Oxaliplatin Imatinib | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency | NCT06090669 | Inherited Bone ... Familial Platel... | imatinib TruSight Oncolo... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study in Adult Ph-positive ALL | NCT04688983 | Acute Lymphobla... | Ponatinib Blinatumomab Imatinib | 55 Years - | Cardiff University | |
| Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy | NCT01865565 | Gastrointestina... | 18 Years - | Chang Gung Memorial Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
